Delphia is developing a precision medicine platform that utilizes activation lethality to exploit the vulnerability of cancer cells through oncogene overactivation. This approach aims to create effective cancer therapies that reduce the risk of resistance mutations commonly seen with traditional targeted treatments.
Funding
$67M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many targeted cancer therapies face challenges due to the rapid emergence of resistance mutations, limiting their long-term effectiveness. Current precision medicine approaches may not fully address the underlying vulnerabilities of cancer cells, leading to relapse and disease progression.
Solution
Delphia is developing a precision medicine platform based on "activation lethality," a novel approach that exploits cancer cells' vulnerability to oncogene overactivation. By intentionally overactivating specific oncogenes, Delphia aims to trigger cell death in cancer cells while minimizing the risk of resistance mutations. This strategy offers the potential for creating more durable and effective cancer therapies compared to traditional targeted treatments. The platform is designed to identify and target key oncogenes that, when overactivated, lead to cancer cell death, providing a new avenue for cancer treatment.
Target Audience
The primary target audience includes cancer patients with limited treatment options, oncologists seeking more effective therapies, and pharmaceutical companies interested in developing novel cancer drugs.
Features
- Identification of specific oncogenes susceptible to activation lethality
- Development of therapeutic agents that selectively overactivate target oncogenes
- Preclinical validation of activation lethality approach in cancer cell lines and animal models
- Platform designed to minimize the development of resistance mutations
- Potential for combination therapies with existing targeted treatments